Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
about
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.Suramin attenuates dystrophin-deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy.A fly in the ointment: reassessing mitotane’s role in the treatment of adrenocortical carcinoma
P2860
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@en
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@nl
type
label
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@en
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@nl
prefLabel
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@en
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@nl
P2093
P2860
P1433
P1476
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
@en
P2093
Derek Raghavan
Renata Costa
Robert Wesolowski
P2860
P304
P356
10.1111/J.1464-410X.2011.10464.X
P577
2011-08-24T00:00:00Z